23andMe Holding Co. (MEUSW)
NASDAQ: MEUSW
· Real-Time Price · USD
1.38
-0.13 (-8.61%)
At close: Apr 24, 2025, 3:47 PM
Company Description
23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development.
It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits.
The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.
23andMe Holding Co.

Country | United States |
IPO Date | Jun 17, 2021 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | n/a |
CEO | Anne Wojcicki |
Contact Details
Address: 223 N. Mathilda Ave. Sunnyvale, California United States | |
Website | http://www.23andme.com |
Stock Details
Ticker Symbol | MEUSW |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001804591 |
CUSIP Number | |
ISIN Number | US90138Q3065 |
Employer ID | 87-1240344 |
SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 01, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 28, 2025 | 8-K | Current Report |
Mar 27, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 26, 2025 | 3 | Filing |
Mar 26, 2025 | 3 | Filing |
Mar 24, 2025 | 8-K | Current Report |
Mar 17, 2025 | SCHEDULE 13D | Filing |
Mar 11, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 10, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |